Urethral bulking agents: a retrospective review of primary versus salvage procedure outcomes

Daly, Ciara M.E.; Mathew, Jini; Aloysious, Judey; Hagen, Suzanne; Tyagi, Veenu; Guerrero, Karen L.

Published in:
World journal of urology

DOI:
[10.1007/s00345-020-03413-7](https://doi.org/10.1007/s00345-020-03413-7)

Publication date:
2021

Document Version
Author accepted manuscript

[Link to publication in ResearchOnline](#)

Citation for published version (Harvard):
Daly, CME, Mathew, J, Aloysious, J, Hagen, S, Tyagi, V & Guerrero, KL 2021, 'Urethral bulking agents: a retrospective review of primary versus salvage procedure outcomes', *World journal of urology*, vol. 39, pp. 2107-2112. <https://doi.org/10.1007/s00345-020-03413-7>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

TITLE PAGE

URETHRAL BULKING AGENTS: A RETROSPECTIVE REVIEW OF PRIMARY
VERSUS SALVAGE PROCEDURE OUTCOMES

Authors

Ciara M. E. Daly¹, Jini Mathew¹, Judey Aloysious¹, Suzanne Hagen¹, Veenu Tyagi¹,
Karen L. Guerrero¹

Affiliations

¹Department of Urogynaecology Queen Elizabeth University Hospital, Glasgow

Corresponding Author

Dr Ciara M.E. Daly. Department of Urogynaecology, Queen Elizabeth University
Hospital, Glasgow, Scotland. Tel – 0141 201 1100. cdaly22@qub.ac.uk

Words 2482

Abstract

Purpose

Urethral Bulking Agents (UBA) have traditionally been offered as salvage procedures for recurrent Stress Urinary Incontinence (SUI). We compare the success of UBA in patients that had undergone a previous procedure for SUI (Salvage-UBA) to the SUI surgery naïve (Primary-UBA). We hypothesised a positive effect in both Primary and Salvage-UBA with potentially poorer rates of response in the salvage group.

Methods

Retrospective case-series of patients having their first UBA (2010–2018). Primary outcome was to assess any difference in patient reported success between groups. Patient reported improvement was assessed on a 4-point scale: ‘cured, improved, no change, worse’ and treatment ‘success’ defined as ‘cured’ or ‘improved’. A multivariate analysis, adjusting for plausible differences between groups was undertaken in IBM SPSS Statistics (2016).

Results

135 Primary-UBA and 38 Salvage-UBA were performed. Complete follow-up was obtained for 114 patients (66%): 86 Primary & 28 Salvage. Median follow-up time: 33-months. In 2012, 47% (8/17) of all UBA were Salvage-UBA, whilst in 2018 the majority were Primary-UBA (92%, 46/50).

Success was not significantly different between Salvage-UBA 75% (21/28) versus Primary-UBA 67% (58/86) (Wald $\chi^2 = 0.687$, df=1, p=0.407). Top-up rates were similar; 14% (n=4/28, Salvage-UBA) versus 15% (n=13/86, Primary-UBA) ($\chi^2 = 0.011$, df=1, p=0.914).

38

39 **Conclusions**

40 The number of women opting for UBA has increased substantially. No significant
41 differences were noted for success with Salvage-UBA compared to Primary-UBA.

42

43 **Keywords**

44 Urethral, Bulking, Incontinence, Primary, Salvage

45

46

MAIN TEXT

Introduction and Purpose

Surgical management of Stress Urinary Incontinence (SUI) is under intense scrutiny. Mesh procedures for SUI were routine until recent years; a current pause is in place within the United Kingdom (UK) (1). Urethral Bulking Agents (UBA) are minimally invasive, non-mesh, day-case or office procedures for SUI. Traditionally, they have been offered as salvage procedures when surgical procedures (e.g. Colposuspension, Autologous Fascial Sling and Mid-Urethral Mesh-Tape) have failed to improve symptoms sufficiently, or when comorbidities make patients unsuitable for these procedures. A Cochrane review (2017) concluded UBA were inferior to surgery for SUI at one-year follow-up but had a better safety profile (2). Despite the inferior success, numbers are on the rise. National statistics from England show a doubling in the number of UBA performed in the last two years (3). For some, UBA may be a desirable first choice procedure for SUI especially if they wish a day-case, non-mesh procedure with a quicker recovery.

Our aim was to compare the success of UBA in patients that had undergone a previous surgical procedure for Stress Urinary Incontinence (Salvage-UBA) to the SUI surgery naïve (Primary-UBA). We hypothesised a positive effect in both Primary and Salvage-UBA with potentially poorer rates of response in the salvage group.

Methods and Materials

Patients having their first UBA treatment (2010–2018) were identified on departmental audit databases. Trakcare[®] electronic notes were then reviewed retrospectively and data collected

70 routinely during standard patient care recorded including: demographics, investigations, agent
71 used, success rates and complications.

72
73 Diagnosis of SUI was with clinical assessment (positive cough-test with comfortably full
74 bladder) or when clinically indicated, with cystometric finding of Urodynamic Stress
75 Incontinence (USI). Symptomatic Voiding Dysfunction (VD) pre-procedure was defined as the
76 patient complaining of: Slow or Intermittent stream / Hesitancy / Terminal Dribble / Straining.
77 VD at Urodynamics was defined as: Flow rate <15mls/ second and/or signs of abdominal
78 straining (with or without incomplete emptying). We have taken a Maximum Urethral Closure
79 Pressure (MUCP) of ≤ 30 cm H₂O as an indicator of Intrinsic Sphincter Deficiency (ISD) (4,5).

80
81 UBA were offered under local anaesthesia (LA), in an ambulatory setting.
82 Anaesthesia consisted of topical Instillagel® 20ml. A further 10ml of Lidocaine 1% injected
83 peri-urethrally, at 3 and 9 o'clock positions, was at the discretion of the operating surgeon. Two
84 agents were used within the department over this time period: Polydimethylsiloxane (Trade
85 name: Macroplastique®, Manufacturer: Cogentix Medical) was the bulking agent used from
86 2010-2017. Polyacrylamide Hydrogel (PAHG) (Trade name: Bulkamid®, Manufacturer:
87 Contura) was introduced in 2016.
88 PAHG was injected trans-urethrally under urethoscopic vision using a 23G x120mm needle
89 surrounded by a rotatable sheath (Bulkamid® system). 1cm markings on the needle aided
90 placement of PAHG blebs 1cm from the urethral orifice. x4 deposits at 2, 5, 7 and 10 o'clock
91 positions were performed (2ml maximum volume), with needle repositioning undertaken to keep
92 sites at the same level/plane to achieve coaptation of the urethra.

Polydimethylsiloxane was administered using an administration device (Macroplastique® - MIS system). Three deposits (5ml maximum volume) were placed at 2, 6 and 10 o'clock positions, trans-urethrally. Trial of void was performed and if residual bladder volumes were less than 150ml (on bladder scan) women were discharged. If there were concerns about VD, patients were taught Clean Intermittent Self Catheterisation (CISC) and discharged. Patients were admitted for intermittent drainage if they were unable to perform CISC.

Post-treatment review was conducted by nurse specialists at approximately 3-months. Top-up injections were administered within 3-6 months after the 1st UBA if the patient was not cured of symptoms and 2nd UBA treatments were defined as those occurring >6months from the 1st UBA.

Primary outcome was the difference in patient-reported success between groups, defined according to patient-reported outcomes on a 4-point scale: cured (defined as no SUI symptoms), improved (defined as sufficiently improved to not wish any alternative surgical treatment), no change (defined as no change or minimal change in symptoms +/- further alternative treatment requested), worse- adapted from the British Society of Urogynaecology (BSUG) audit database (6). Treatment 'success' was defined as cured or improved, assessed at the first clinic follow-up appointment (at approximately 3-months).

Secondary Outcomes included: 'top-up' injection requirement, complications (post-procedure VD, Urinary Tract Infection (UTI) and urethral pain rates), change in Overactive Bladder (OAB) symptoms (cured, improved, no change, worse, new onset), change in the 'International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form' (ICIQ-UI SF) scores, duration of treatment success and further management for SUI post UBA therapy.

IBM SPSS version 24 (2016) was used to perform multivariable binary logistic regression modelling to examine the effect of patient type (Primary versus Salvage-UBA) on the outcome of cure or improved (combined to assess 'success') versus no change. The model adjusted for age, bladder symptom type (SUI/ MUI), method of diagnosis (clinical versus urodynamics), operator grade (consultant versus trainee supervised procedure), time to follow-up, and agent used (PAHG versus Polydimethylsiloxane). Variables with a high proportion of missing data (BMI, MUCP and baseline ICIQ-UI SF score) were excluded to maintain analysis validity however none of these variables was individually associated with the outcome in a univariate analysis (see Online Resource 1). Graphpad Prism 8.1.2 was used to assess any differences in secondary outcomes (paired t-test for change in ICIQ-UI SF score, Chi-squared/ Fisher's Exact for categorical data and Mann-Whitney U for data which were not normally distributed. A significance level of 5% was used throughout.

Results

We identified 173 women over this time period (n=170 with documented type of agent). Primary-UBA and 38 Salvage-UBA were performed. Mean age was 60 years and mean BMI=30. 89% of procedures were performed under local anaesthesia (2 with concurrent sedation).

There has been a greater than four-fold rise in the number of UBA performed on an average of 11 per year between 2010 and 2016 to 48 per year between 2017 and 2018. Furthermore, in

2012 almost half (47%) of all UBA were salvage-type, whilst in 2018 the majority are Primary-UBA (92%).

In the salvage group, patients had undergone a wide range of surgical treatments for SUI (Fig1.docx), including some with multiple previous operations.

Patients awaiting follow-up and those who did not attend for follow-up were excluded.

Complete follow-up was therefore obtained for 114 patients (n=86 Primary, n= 28 Salvage).

Median follow-up time from date of injection to date of study (October 2018) was 33 months (Interquartile range: 46 months). Median follow-up time for Primary-UBA: 24 months, Salvage-UBA: 56 months.

Primary Outcome

Initial success at follow-up was 75% versus 67% in the Salvage-UBA and Primary-UBA groups respectively. Additional data are given in Online Resource 2. In the logistic regression analysis there was no significant association between type of patient (Primary or Salvage-UBA) and the success (cured or improved versus no change) (Wald $\chi^2= 0.687$, df=1, p=0.407) (Table 1).

Secondary Outcomes

Similar top-up rates (second injection) were seen; 14% (n=4/28) versus 15% (n=13/86) respectively ($\chi^2= 0.011$, df=1, p=0.914). Outcomes from top-ups in Primary-UBA: success n=5, no change n=3, awaiting FU n=5 and Salvage UBA: success=1, no change n=2, awaiting FU n=1. No patient's symptoms worsened following top-up.

161
 162 Transient post-procedure VD was higher in the Salvage-UBA group (21% versus 13%) but was
 163 not statistically significantly different ($\chi^2 = 1.384$, df=1, p=0.239). Median duration of CISC use
 164 was 2.5 days (range 1-14 days) and differed by one day between groups (Primary-UBA: 2 days,
 165 Salvage-UBA: 3.5 days).
 166 The incidence of VD was highest overall for those who had symptomatic VD pre-operatively
 167 (n=12/68; incidence with Primary-UBA 22%, n=11/50 and Salvage-UBA 11%, n=2/18). In those
 168 who were asymptomatic pre-operatively, VD still occurred in 12% (n=13/105) and was higher
 169 for those in the salvage group (30%, n=6/20) compared to the Primary-UBA group (8%, n=7/85).
 170 In women with urodynamic VD, the risk of transient post-operative VD was lower overall at
 171 10%, n=2/21 (Incidence with Primary-UBA: 7%, n=1/14 and Salvage-UBA: 14%, n=1/7).
 172 Post-procedure VD was not seen in the top-up groups.
 173 Following a 2nd treatment course, post-procedure VD overall was 32% (n=10/32); 30% (n=3/10)
 174 in Salvage-UBA and 32% (n=7/22) in Primary-UBA cases.
 175 Other complications rates were low, namely: UTI (n=1) treated with an oral antibiotic course and
 176 transient urethral pain (n=2) at the time of administration was seen in both groups and settled
 177 with expectant management rapidly post procedure.
 178 No patient reported new or worsening overactive bladder (OAB) symptoms in either group. 7
 179 patients did undergo OAB treatment at follow-up; all had prior stress-predominant, mixed
 180 urinary incontinence (MUI) and wished to address the OAB component following treatment for
 181 SUI and after trying conservative measures.

ICIQ-UI SF questionnaires were poorly completed at 3-month follow-up, allowing only 13 pre and post treatment pairs. Statistically significant reductions in pre and post-treatment ICIQ-UI SF scores were seen overall (Paired t-test $t=4.107$, $df=12$, $p=0.0015^*$), although this needs to be interpreted with caution due to the small numbers.

Despite any initial success, 36% ($n=10$) of Salvage-UBA versus 26% ($n=22$) of Primary-UBA ultimately underwent a 2nd treatment course ($\chi^2=1.074$, $df=1$, $p=0.300$). Median time to 2nd treatment course was 11 months: Salvage-UBAs median time was 10 months (interquartile range 7-20 months) and 11 months with Primary-UBAs (interquartile range 8-14 months), $p=0.635$ (Mann-Whitney test). 21 completed 3-month follow-up after a 2nd treatment course; overall success was slightly poorer at 62% ($n=13/21$), 88% ($n=7/8$) success with Salvage-UBA versus 46% ($n=6/13$) with Primary-UBA. 20 patients proceeded to alternative SUI surgery during the study follow-up: Salvage-UBA ($n=8/28$, 29%), Primary-UBA ($n=12/86$, 14%) (Fishers Exact, $p=0.908$). Alternative procedures in the Primary-UBA group included: 4 mid-urethral tapes, 5 autologous fascial slings and 3 colposuspension procedures. In the Salvage-UBA group: 3 underwent mid-urethral tapes, 4 autologous fascial slings and 1 patient had colposuspension.

Discussion

We have seen an accelerated use of UBAs which may be due to current government restrictions on transvaginal mesh in this country (1). A UK review into surgical practice highlighted certain criteria to be met prior to lifting restrictions (7). Furthermore, the National Institute for Clinical Excellence (NICE) guidelines (8) advises offering all surgical options and multidisciplinary team

approach. These aspects and the medicolegal environment may have resulted in a shift in treatment preferences.

Literature reviews (9–12), of UBAs suggest short-term efficacy is encouraging, however, overall success rates wane over time with repeat injections required. Retrospective studies have shown subjective short-term response with UBA to be 71-84% for those who have had prior SUI surgery (13,14). This is comparable to rates reported in primary SUI cases (71-82% at 6 months and 3 months respectively) (15,16). Reported success is similar to our cases with comparable success for Primary and Salvage-UBA procedures (67-75%) but with slightly lower success for Primary-UBA. Cure rates in our study (8%) are lower than published studies however $\geq 2/3$ of women were significantly improved to decline further management. Lower cure rate may be due to differences in the populations studied with lower BMI (mean= 25, range 22-27) and younger women (mean= 49 years, range 42-60) in one randomised trial (17). This is in contrast to mean BMI=30 and mean age = 60 years in our study.

Particulate UBAs are made from solid microparticles in an absorbable liquid/gel carrier whereas non-particulate UBAs rely on host cells entering the hydrogel to form a network of fibers for anchorage (18). With a constant exchange of water molecules from surrounding tissues, non-particulate UBAs mechanistically resist absorption (18), staying in place over time.

Two agents were used in our study. The first, PAHG (Bulkamid ®) is non-particulate, made of 97.5% water and 2.5% cross-linked polyacrylamide. Studies vary in short term (3-6 month) subjective responder rate when used as a Primary-UBA, ranging from 71% (16), (19), to 82% (15). In a study by Sokol et al (20) 12-month follow-up had a 77% subjective cure/ improvement rate and a 17% acute urinary retention event rate affecting 5.7% of patients.

227 The 2nd agent, Polydimethylsiloxone (Macroplastique ®) has a silicone particulate (2). In a
228 systematic review and meta-analysis by Ghoniem success was 75% (<6 months) and 64% (>
229 18months). Typical reinjection rate was 30% and high reinjection rates were associated with
230 better long-term success (21). In our study, the use of PAHG was more common in the Primary-
231 UBA group (~2/3 of cases) than the Salvage-UBA (~1/2 of cases), reflecting the rise in Primary-
232 UBA over the last 2 years. The change of agent in 2016 was based on a previous department
233 review (22), showing high reinjection rates due to early recurrence of symptoms (30%).
234 Notably, agent type did not contribute to any significant differences in outcomes between groups
235 in the logistic regression analysis.

236 Studies have varied in timing of and the terms used in reporting repeat injections. Pai and Al-
237 Singury (15) reported ‘no *booster* was offered when there was no improvement but good
238 coaptation at surgery’. The Standard Operating Procedure for PAHG suggests if a ‘*top-up*’ is
239 required to improve treatment efficacy, this can be carried out at 4-6 weeks following 1st
240 injection. Other studies ((19,20) have reported 2nd and 3rd *reinjection* requirement rates (not
241 using ‘top-up’), with a 2nd injection rate of 35% at 6-8 weeks following 1st UBA (19) and a 3rd
242 injection rate of 35.8% if not dry after 1st+/- 2nd bulking (repeat injections administered at a mean
243 35 days after previous injections) (20). Standardisation of follow-up assessment points and
244 reporting would allow better comparisons of outcomes across studies.

245 In this study salvage-UBA tended to lose more effect over time with 36% vs 26% of Primary-
246 UBA proceeding to have a 2nd treatment course. These were repeated at about one year and
247 results did not reach statistical significance between groups.

The rate of voiding dysfunction in this study (15%) is higher than previously reported. Most of our procedures are performed under LA in ambulatory care. A strict local policy with early recourse to CISC (PVR >150ml), may have impacted on our results.

This was a single-institution, retrospective study which did not have a control group. Additionally, primary outcome was assessed at 3 months (short-term). We do acknowledge that these are sources of potential bias and limitations of our study. ICIQ-UI SF was poorly completed post-procedure, which is being addressed locally. Objective assessment with urodynamics post-procedure has been used when reporting outcomes for UBA, however, has tended to show more favourable success. Subjective patient responses capture the crucial impact on quality of life for the patient which we have used in this study - this is arguably more important (12).

Overall, this study reports a moderate subjective success (67-75%) for both Primary and Salvage-UBAs with no significant differences in success between these groups, however, further work is needed. The number of women opting for UBA has increased substantially with 92% of procedures performed as primary SUI procedures in 2018. With the uptake in UBA as a primary choice, follow-up of any impact on future SUI surgical procedures has not been established. More than ever, long-term outcomes should be a priority for all UBA research. These will inform patient safety with UBA and aid counselling on the success longevity for these agents.

DECLARATIONS

Funding

271 Nil received

272

273 **Availability of data and material**

274 Not available

275

276 **Consent to participate**

277 Not applicable given study design

278

279 **Consent for publication:**

280 Not applicable

281

282 **Code availability**

283 Not available

284

285 **Conflicts of interest**

286 Authors JM and JA have no conflicts of interest. Authors CMED, VT and KLG have received

287 funding/sponsorship from Contura Ltd. for attendances at educational conferences & meetings.

288

289 **Ethics approval**

290 In view of the retrospective nature of the study and all the procedures being performed were part

291 of the routine care, this study did not meet requirements for ethical approval according to the

292 Health Research Authority decision tool.

293

Authors' contributions

Daly C. M. E: Project development, Analysis of Results, Manuscript writing/ editing.

Aloysious J: Data collection, Manuscript editing.

Mathews J: Data collection, Manuscript editing.

Hagen S: Data Analysis, Manuscript editing.

Tyagi V: Project Development & Manuscript editing.

Guerrero K. L: Project development, Manuscript writing/ editing.

CAPTIONS

Fig.1 Type of Previous Stress Urinary Incontinence Procedure in the Salvage-UBA group

Table 1. Multivariable Logistic Regression Analysis

Online Resource 1. Univariate analysis of BMI, MUCP and ICIQ-UI SF variables on primary outcome

Online Resource 2. Primary Outcome for Primary and Salvage-UBA groups

REFERENCES

1. Medicines and Healthcare products Regulatory Authority. Pause on the use of vaginally inserted mesh for stress urinary incontinence [Internet]. United Kingdom: GOV.UK; [cited 2018 July 17]. Available from URL:<https://www.gov.uk/government/news/pause-on-the-use-of-vaginally-inserted-surgical-mesh-for-stress-urinary-incontinence>
2. Kirchin V, Page T, Keegan PE, Atiemo KO, Cody JD, McClinton S, et al. Urethral injection therapy for urinary incontinence in women. *Cochrane Database of Systematic Reviews*. [Online] 2017;7(7): CD003881. Available from: doi:10.1002/14651858.cd003881.pub4
3. Zacche MM, Mukhopadhyay S, Giarenis I. Changing surgical trends for female stress urinary incontinence in England. *International Urogynecology Journal*. [Online] 2019;30(2): 203–209. Available from: doi:10.1007/s00192-018-3839-4
4. Smith PP, Leijssen SAL van, Heesakkers JPFA, Abrams P, Smith ARB. Can we, and do we need to, define bladder neck hypermobility and intrinsic sphincteric deficiency?: ICI-RS 2011. *Neurourology and Urodynamics*. [Online] 2012;31(3): 309–312. Available from: doi:10.1002/nau.22220
5. Krissi H, Pansky M, Halperin R, Langer R. Maximal urethral closure pressure < 20 cm H₂O: does it predict intrinsic sphincteric deficiency? *The Journal of reproductive medicine*. 2005;50(11): 824–826.
6. Moran P, Foon R, Assassa P. The BSUG national database: concept, design, implementation and beyond. *The Obstetrician & Gynaecologist*. [Online] 2013;15(2): 120–127. Available from: doi:10.1111/tog.12004

338 7. IMMDS. *First do no harm -The report of the Independent Medicines and Medical Devices*
339 *Safety (IMMDS)Review*. [Online] 2020 Aug p. 1–277. Available from:
340 https://www.immidsreview.org.uk/downloads/IMMDSReview_Web.pdf

341 8. NICE Guidance – Urinary incontinence and pelvic organ prolapse in women: management.
342 *BJU International*. [Online] 2019;123(5): 777–803. Available from: doi:10.1111/bju.14763

343 9. Li H, Westney OL. Injection of Urethral Bulking Agents. *Urologic Clinics of North America*.
344 [Online] 2019;46(1): 1–15. Available from: doi:10.1016/j.ucl.2018.08.012

345 10. Hussain SM, Bray R. Urethral bulking agents for female stress urinary incontinence.
346 *Neurourology and Urodynamics*. [Online] 2019;38(3): 887–892. Available from:
347 doi:10.1002/nau.23924

348 11. Kasi AD, Pergialiotis V, Perrea DN, Khunda A, Doumouchtsis SK. Polyacrylamide hydrogel
349 (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature.
350 *International Urogynecology Journal*. [Online] 2016;27(3): 367–375. Available from:
351 doi:10.1007/s00192-015-2781-y

352 12. Mohr S, Siegenthaler M, Mueller MD, Kuhn A. Bulking agents: an analysis of 500 cases and
353 review of the literature. *International Urogynecology Journal*. [Online] 2013;24(2): 241–247.
354 Available from: doi:10.1007/s00192-012-1834-8

355 13. Dray EV, Hall M, Covalschi D, Cameron AP. CAN URETHRAL BULKING AGENTS
356 SALVAGE FAILED SLINGS? *Urology*. [Online] 2018;(Obstet Gynecol 111 2 Pt 1 2008).
357 Available from: doi:10.1016/j.urology.2018.09.019

358 14. Zivanovic I, Rautenberg O, Lobodasch K, Büнау G von, Walser C, Viereck V. Urethral
359 bulking for recurrent stress urinary incontinence after midurethral sling failure. *Neurourology*
360 *and Urodynamics*. [Online] 2017;36(3): 722–726. Available from: doi:10.1002/nau.23007

361 15. Pai A, Al-Singary W. Durability, safety and efficacy of polyacrylamide hydrogel
362 (Bulkamid®) in the management of stress and mixed urinary incontinence: three year follow up
363 outcomes. *Central European Journal of Urology*. [Online] 2015;68(4): 428–433. Available
364 from: doi:10.5173/ceju.2015.647

365 16. Lose G, Sørensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T. An open
366 multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and mixed urinary
367 incontinence. *International Urogynecology Journal*. [Online] 2010;21(12): 1471–1477.
368 Available from: doi:10.1007/s00192-010-1214-1

369 17. Freitas A-MI, Mentula M, Rahkola-Soisalo P, Tulokas S, Mikkola TS. Tension-Free Vaginal
370 Tape Surgery versus Polyacrylamide Hydrogel Injection for Primary Stress Urinary
371 Incontinence: A Randomized Clinical Trial. *The Journal of urology*. [Online] 2019;203(2): 372–
372 378. Available from: doi:10.1097/ju.0000000000000517

373 18. Chapple C, Dmochowski R. Particulate Versus Non-Particulate Bulking Agents In The
374 Treatment Of Stress Urinary Incontinence. *Research and Reports in Urology*. [Online]
375 2019;Volume 11: 299–310. Available from: doi:10.2147/rru.s220216

376 19. Toozs-Hobson P, Al-Singary W, Fynes M, Tegerstedt G, Lose G. Two-year follow-up of an
377 open-label multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and
378 stress-predominant mixed incontinence. *International Urogynecology Journal*. [Online]
379 2012;23(10): 1373–1378. Available from: doi:10.1007/s00192-012-1761-8

380 20. Sokol ER, Karram MM, Dmochowski R. Efficacy and Safety of Polyacrylamide Hydrogel
381 for the Treatment of Female Stress Incontinence: A Randomized, Prospective, Multicenter North
382 American Study. *The Journal of Urology*. [Online] 2014;192(3): 843–849. Available from:
383 doi:10.1016/j.juro.2014.03.109

- 384 21. Ghoniem GM, Miller CJ. A systematic review and meta-analysis of Macroplastique for
385 treating female stress urinary incontinence. *International Urogynecology Journal*. [Online]
386 2013;24(1): 27–36. Available from: doi:10.1007/s00192-012-1825-9
- 387 22. Scott V, Tyagi V, Guerrero K. *Bladder Neck Injections for Stress Urinary Incontinence; A*
388 *Retrospective Cohort Study*. [Online] 2016. Available from: <https://www.ics.org/2016/slot/15935>
- 389